Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 6/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | UBE2M | P61081 | 7/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274779 | 0.85 | KCNH2 (0.59) | KCNH2CACNA1ICCR2 | |
| SCHEMBL16458438 | 0.84 | KCNH2 (0.50) | KCNH2CACNA1ICCR2 | |
| SCHEMBL14770254 | 0.83 | KCNH2 (0.58) | KCNH2CACNA1I | |
| SCHEMBL4282547 | 0.76 | KCNH2 (0.58) | KCNH2CACNA1I | |
| SCHEMBL4275358 | 0.75 | KCNH2 (0.56) | KCNH2CACNA1I | |
| SCHEMBL4269991 | 0.74 | CACNA1I (0.60) | KCNH2CACNA1I | |
| SCHEMBL13569827 | 0.73 | CACNA1I (0.46) | KCNH2CACNA1I | |
| SCHEMBL4277277 | 0.73 | CACNA1I (0.63) | KCNH2CACNA1I | |
| SCHEMBL4279865 | 0.72 | CACNA1I (0.60) | KCNH2CACNA1IUBE2MDCUN1D1 | |
| SCHEMBL19112605 | 0.72 | KCNH2 (0.52) | KCNH2CACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1I 4/4885BDKRB1 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.